Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease,...
Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9639 6036
Fax: 61 3 9639 6030
Address:
55 Collins Street, Level 38, Melbourne, Australia
